Scleroderma
162
26
28
84
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
23 trials with published results (14%)
Research Maturity
84 completed trials (52% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.6%
14 terminated out of 162 trials
85.7%
-0.8% vs benchmark
9%
14 trials in Phase 3/4
27%
23 of 84 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 84 completed trials
Clinical Trials (162)
Brentuximab Vedotin for Systemic Sclerosis
MRI for Screening and Monitoring Scleroderma ILD
Elastography Ultrasound in Localized Scleroderma (Morphea) Study
Brain Boost Program to Improve Cognitive Function in People With Systemic Sclerosis
Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
Hyaluronidase Via LADD Scleroderma-induced Microstomia
Pregnancy and Medically Assisted Conception in Rare Diseases
MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
Rheumatology Patient Registry and Biorepository
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
Platform Clinical Study for Conquering Scleroderma
Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma
Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
Yoga Adjunct for Scleroderma